Sidewinder Nabs $137M to Advance Precision Cancer 'Smart Bomb' ADCs

SAN DIEGO, CA – April 08, 2026 – Sidewinder Therapeutics, a San Diego-based biopharmaceutical firm, has secured a landmark $137 million in an oversubscribed Series B financing round to propel its next-generation cancer therapies into clinical development. The funding, co-led by heavyweights Frazier Life Sciences and Novartis Venture Fund, underscores soaring investor confidence in the company’s innovative approach to designing highly specific antibody-drug conjugates (ADCs) aimed at some of the most difficult-to-treat solid tumors.

The financing brings Sidewinder's total capital raised to $162 million since its 2023 inception and assembles a powerful syndicate of new and existing investors, including Goldman Sachs Alternatives, DCVC Bio, and OrbiMed. The capital infusion is set to fuel the company's mission to redefine the ADC landscape, with its lead candidate slated to enter human trials in 2027.

“The ADC field is at an inflection point driven by technological breakthroughs enabling next-generation bispecific ADCs, and Sidewinder is eager to lead this wave of innovation,” said Eric Murphy, Ph.D., Co-Founder and CEO of Sidewinder Therapeutics, in a statement.

A New Wave of 'Smart Bomb' Cancer Drugs

For years, ADCs have been heralded as “smart bombs” in oncology—therapies designed to act as guided missiles that deliver potent cytotoxic payloads directly to cancer cells while sparing healthy tissue. A traditional ADC consists of a monoclonal antibody linked to a cancer-killing drug. The antibody seeks out a specific antigen, or target, on the surface of tumor cells. However, this first generation of ADCs has faced limitations. Many targets are also present on healthy cells, leading to off-target toxicity, and some tumors develop resistance by reducing the expression of the target antigen.

Sidewinder is at the forefront of a new strategy designed to overcome these hurdles: bispecific ADCs (BsADCs). Instead of recognizing just one target, Sidewinder’s therapies are engineered to bind to two distinct proteins simultaneously. This dual-targeting mechanism dramatically increases precision. The company's platform focuses on identifying and targeting unique “receptor co-complexes”—pairs of receptors that are highly expressed together on certain solid tumors but not on normal cells. This approach acts like a two-key security system, ensuring the drug is delivered only when both targets are present, which enhances both tumor cell specificity and the rate at which the drug is internalized by the cancer cell.

This scientific sophistication is bolstered by a key strategic partnership. Sidewinder is leveraging Lonza's clinically validated Synaffix platform, which provides advanced, site-specific linker technologies. This technology ensures the cytotoxic payload is attached to the antibody in a precise and stable manner, creating a more homogenous and predictable drug with a potentially wider therapeutic window—meaning it can be more effective at lower, safer doses.

A Bullish Bet on Biotech's Next Big Thing

The oversubscribed nature of the $137 million round is a powerful market signal. In a selective biotech funding environment, the ability to attract such a high-caliber group of investors speaks volumes about the perceived value of Sidewinder's platform. The syndicate includes not only top-tier life science venture firms like Frazier and OrbiMed but also the strategic venture arm of pharmaceutical giant Novartis and the formidable life sciences division of Goldman Sachs Alternatives.

“Founded on compelling science and a differentiated approach, Sidewinder’s novel bispecific ADC pipeline has the potential to address key hurdles limiting safety and efficacy for this class of therapeutics,” noted Daniel Estes, Ph.D., General Partner at Frazier Life Sciences. “We believe that Sidewinder Therapeutics will significantly advance the ADC space and is well positioned to transform the treatment paradigm for cancer patients.”

This investment is more than just capital; it's a strategic alignment. Concurrent with the financing, the company has bolstered its Board of Directors with seasoned experts, including Dr. Estes, Michal Silverberg from Novartis Venture Fund, Josh Richardson, M.D., from Goldman Sachs, and John Hamer, Ph.D., from DCVC Bio. This new brain trust, joining a leadership team led by serial life science entrepreneur Dr. Eric Murphy, provides a deep well of scientific, clinical, and commercial expertise to guide the company through the complex journey of drug development.

Targeting Cancers with Few Good Options

Beyond the sophisticated science and strong financial backing, the ultimate promise of Sidewinder's work lies in its potential impact on patients. The company has set its sights on cancers where the unmet medical need is profound and existing treatment options are limited. Initial programs are focused on squamous cell carcinomas, which include aggressive forms of lung and head and neck cancer, as well as gastrointestinal cancers like colorectal cancer.

These diseases represent a significant global health burden. Gastrointestinal cancers alone account for one in four cancer cases and one in three cancer deaths worldwide. Squamous cell carcinomas are notoriously aggressive, with high rates of recurrence and mortality. For many patients diagnosed with these cancers in advanced stages, the prognosis remains poor, highlighting the urgent need for new therapeutic strategies.

Sidewinder's preclinical data has already shown promise. Its lead candidates, such as SWT019 for lung cancer and SWT020 for colorectal cancer, have demonstrated significantly improved internalization into cancer cells compared to their monospecific counterparts. The company is on a clear trajectory to translate this science into clinical reality, with plans to file an Investigational New Drug (IND) application for its lead program in the first half of 2027.

While the path from a preclinical concept to an FDA-approved drug is long and fraught with challenges, Sidewinder Therapeutics has assembled the critical components for success: a scientifically differentiated platform, substantial financial resources from a world-class investor base, and an experienced leadership team. For patients battling some of the most formidable cancers, this combination represents a significant new source of hope on the horizon.